Background: Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients.
Methods And Results: We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for heart failure (520 versus 604; hazard ratio, 0.84; 95% confidence interval, 0.74-0.94; P=0.003) or an emergency department visit for worsening heart failure (hazard ratio, 0.66; 95% confidence interval, 0.52-0.85; P=0.001). The patients in the LCZ696 group had 23% fewer hospitalizations for worsening heart failure (851 versus 1079; P<0.001) and were less likely to require intensive care (768 versus 879; 18% rate reduction, P=0.005), to receive intravenous positive inotropic agents (31% risk reduction, P<0.001), and to have implantation of a heart failure device or cardiac transplantation (22% risk reduction, P=0.07). The reduction in heart failure hospitalization with LCZ696 was evident within the first 30 days after randomization. Worsening of symptom scores in surviving patients was consistently more common in the enalapril group. LCZ696 led to an early and sustained reduction in biomarkers of myocardial wall stress and injury (N-terminal pro-B-type natriuretic peptide and troponin) versus enalapril.
Conclusions: Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotensin-converting enzyme inhibition.
Clinical Trial Registration Url: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013748 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Podcast on Patient and Physician Perspectives in the Holistic Care of Heart-Related Challenges of Type 2 Diabetes.
Diabetes Ther
December 2024
Patient Author, Heart Sistas, North Lauderdale, FL, USA.
Type 2 diabetes (T2D) frequently coexists with cardiorenal complications. Therefore, a holistic approach to patient management is required, with specialists such as primary care physicians, cardiologists, endocrinologists, and nephrologists working together to provide patient care. Although glycemic control is important in the management of T2D, patients with T2D and acceptable glycemic control are still at risk from cardiovascular (CV) events such as stroke, heart attack, and heart failure (HF).
View Article and Find Full Text PDFEarly Improvement in Cardiac Function and Dyssynchrony After Physiological Upgrading in Pacing-Induced Cardiomyopathy.
Pacing Clin Electrophysiol
December 2024
Arrhythmia Unit, Department of Cardiology, Hospital Juan Ramón Jiménez, Huelva, Spain.
Background: Interventricular dyssynchrony derived from the classic non-physiological stimulation (n-PS) of the right ventricle (RV) is a known cause of left ventricular dysfunction (LVDys).
Methods: This was a prospective descriptive single-center study. We analyzed patients who develop LVDys with n-PS, and the results after upgrading to conduction system pacing (CSP).
Diagnostic and prognostic potential of left atrial strain in cardiovascular disease: a narrative review.
J Echocardiogr
December 2024
Department of Cardiology, Lebanese American University Medical Center - Rizk Hospital, Beirut, Lebanon.
Left atrial strain (LAS) was recently introduced as a parameter that reflects on left atrial function. Consequently, changes in LAS can inform the development of cardiovascular diseases, hence providing a window for non-invasive and cost-effective testing of these diseases and their complications at early stages of development, potentially offering a segway towards preventive interventions. LAS has yet to be implemented into standard practice.
View Article and Find Full Text PDF[Nonagenarians on an emergency department for internal medicine and cardiology : Comparison of comorbidities, disease course and survival with younger patients].
Z Gerontol Geriatr
December 2024
2. Med. Abteilung, Klinik Landstraße, Juchgasse 25, 1030, Wien, Österreich.
Background: Little is known about how younger and older hospitalized patients differ with respect to reasons for admission, comorbidities, diagnostics, treatment and intercurrent problems.
Objective: The aim of the study was to compare the previously named characteristics in the clinical profile of patients > 90 years old (nonagenarians) with a control group of patients 70-75 years old admitted to an emergency hospital department for internal medicine and cardiology.
Material And Method: The study included all consecutive nonagenarians and gender-matched control patients who were admitted during 2011.
Defibrillation Testing in Patients Undergoing Replacement of the S-ICD Generator: Is There Still a Need?
Pacing Clin Electrophysiol
December 2024
Department of Cardiology II - Electrophysiology, University Hospital Münster, Münster, Germany.
Background: Noninferiority of omitting intraoperative defibrillation threshold (DFT) testing has been documented for transvenous implantable cardioverter defibrillators (ICD) whereas data for the subcutaneous-ICD (S-ICD) regarding the need for DFT testing, especially during S-ICD generator replacement, is not available.
Methods: A total of 112 consecutive patients who underwent S-ICD generator replacement and routine testing were included in this retrospective single-center study and analyzed regarding the outcome of intraoperative DFT.
Results: The majority of patients (87.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!